CD274 and neoplasm: PD-L1-SARS vaccination activates both Th1 and Th2 responses and induces antibodies that selectively recognize degraded PD-L1 peptides from apoptotic tumor cells, without targeting membrane-bound PD-L1 or interfering with ICIs.